Results: 129 patients with IPF (IPF/UIP 44, clinical IPF 85) were enrolled this study, excluded 25 patients with IPF diagnosed by disease behavior (unclassifiable IIPs 8, IPPFE 6, INSIP 1, chronic hypersensitivity pneumonia 7, other diseases 3). Median time from diagnosis to starting pirfenidone was 6.9 (IQR 2.1-84.8) weeks. 59 patients were treated more than 52 weeks {median treated periods was 117 (IQR 79-185) weeks}. Median decline of FVC was 90 (IQR−7 -303) ml/year. Median survival time from stating pirfenidone and diagnosis was 4.1 and 6.8 years, respectively. Acute exacerbation ratio was 26% in all patients. Discontinuation ratio was 41% at 52 weeks and 62% at whole periods.
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Background and Aims: Pulmonary alveolar proteinosis (PAP) is a rare lung disease and data on prevalence and incidence of PAP are limited. The aim of this study is to investigate the prevalence and incidence of PAP by using nationwide claims data from Korean health insurance review and assessment service.
Methods: Cases of PAP were identified for any visit between 2010 to 2016 that listed the Korean Classification of Disease, 7th edition code of PAP (J84.0) and rare incurable disease exempted calculation code (V222). A narrow case was defined as follows: 1) more than two PAPcoded visits within 1 year of the first claim, 2) more than one claim for both chest computed tomography and diagnostic procedures (bronchoscopy or surgical lung biopsy) within 90 days of the first claim.
Results: A total of 182 patients (narrow, n = 82) visited medical institutions for PAP during the study period, and 89 patients (narrow, n = 66) were newly identified between 2012 and 2016. The prevalence of PAP was 4.44 (narrow: 4.39) per 10 6 people and was highest between ages 60-69 years. The incidence was 0.56 (narrow: 0.41) per 10 6 personyears, with the highest incidence rate between ages 50-59 years. The age-and sex-standardized annual incidence rates were constant from 0.56 (narrow: 0.45) per 10 6 person-years in 2012 to 0.52 (narrow: 0.39) per 10 6 person-years (figure). The highest incidence peak in men and women were 50-59 years, but the age distribution in women showed bimodal pattern due to second incidence peak in 20-29 years. For incidence cases, mean age was 50.8 years, the highest peak age was 50-59 years, and male predominance was observed (male-to-female ratio: 1.82).
Conclusion:
The prevalence and incidence of PAP in Korea were low, similarly to those in other countries, and middle-aged men showed the highest risk. 
